10900 WILSHIRE BLVD, LOS ANGELES, CA
Reports Second Quarter 2026 Financial Results
Director Elections and Crowe LLP Appointment Ratified at Annual Meeting
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Increases Share Repurchase Program to $20 Million
Investor Presentation
To Streamline and Focus its Operations with the Sale of Reference Standards Business to LGC in All-Cash Transaction
Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order